Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDKN2A del |
Therapy | Palbociclib |
Indication/Tumor Type | high grade glioma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A del | high grade glioma | sensitive | Palbociclib | Preclinical - Cell culture | Actionable | In a preclinical study, Ibrance (palbociclib) inhibited viability in glioma cell lines harboring IDH1 R132H and deletion of CDKN2A in culture (PMID: 38718141). | 38718141 |
PubMed Id | Reference Title | Details |
---|---|---|
(38718141) | CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition. | Full reference... |